Monday, May 16, 2022
5/16/2022
Project summary In the heart, the primary function of mitochondria is to meet the high energy demand of the beating myocytes by providing ATP through oxidative phosphorylation. However, mitochondria can quickly change into death-promoting organelles. Not surprisingly, cells have developed multiple defense mechanisms against aberrant mitochondria that can cause harm to the cell. The ability to eliminate dysfunctional mitochondria and prevent unnecessary death is particularly important in post-mitotic myocytes that cannot be easily replaced. It is well established that dysfunctional mitochondria are rapidly sequestered by autophagosomes and subsequently delivered to lysosomes for degradation. Recent studies have identified cells that can also eliminate mitochondria via a Rab9-dependent alternative autophagy pathway or via a Rab5-dependent-early endosomal pathway. Mitochondria can also be directly taken up by lysosomes. Clearly, multiple pathways of mitochondrial elimination exist in cells to prevent their accumulation and ensure survival. However, these degradation pathways all converge at the level of the lysosomes and it is not clear whether alternative mitochondrial quality control pathways exists when lysosomal function is compromised. We have discovered that dysfunctional mitochondria can also be secreted from cells when internal degradation pathways are overwhelmed or impaired. Our preliminary data demonstrate that Rab7-/- and LAMP2-/- cells that have impaired lysosomal degradation are still able to efficiently eliminate depolarized mitochondria. We also found increased levels of circulating extracellular vesicles (EVs) containing mitochondria in plasma after a myocardial infarction, as well as in cardiac specific Rab7- and LAMP2-deficient mice at baseline. Proteomics analysis of EVs combined with Western blot analysis suggest that the mitochondria are in vesicles that originate from the endosomal pathway. In this proposal, we will investigate the hypothesis that dysfunctional mitochondria are secreted from cells in EVs and that this represent an important quality control pathway in the heart that can compensate when lysosomes are overwhelmed or compromised. This hypothesis will be tested with two specific aims. Specific aim 1 will identify the origin and fate of the extracellular vesicles containing mitochondria and determine the pathophysiological conditions that induce their release from myocytes. Specific aim 2 will dissect the molecular mechanisms regulating secretion of mitochondria in EVs. Overall, these studies will provide important new insights into a novel alternative mechanism of mitochondrial elimination in the myocardium. The studies will also provide insights into whether these EVs can potentially function as early diagnostic biomarkers of cardiac stress prior to development of disease.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
